Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone

IF 8.9 1区医学

Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2024-12-17 DOI:10.1002/jcsm.13665

Sanghoon Bae, Van-Hieu Mai, Seyoung Mun, Dalong Dong, Kyudong Han, Sunghyouk Park, Jung Keun Hyun

引用次数: 0

Abstract

Muscle atrophy, including glucocorticoid-induced muscle wasting from treatments such as dexamethasone (DEX), results in significant reductions in muscle mass, strength and function. This study investigates the potential of lonafarnib, a farnesyltransferase inhibitor, to counteract DEX-induced muscle atrophy by targeting key signalling pathways.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cachexia, Sarcopenia and Muscle Medicine-Orthopedics and Sports Medicine

自引率

12.40%

发文量

期刊介绍： The Journal of Cachexia, Sarcopenia, and Muscle is a prestigious, peer-reviewed international publication committed to disseminating research and clinical insights pertaining to cachexia, sarcopenia, body composition, and the physiological and pathophysiological alterations occurring throughout the lifespan and in various illnesses across the spectrum of life sciences. This journal serves as a valuable resource for physicians, biochemists, biologists, dieticians, pharmacologists, and students alike.